SCHEMBL5578796

SCHEMBL5578796

Cc1ccc(CN2CC3(CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)c3ccccc32)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.43
LMNA P02545 3/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.42
OXTR P30559 1/20 0.41
HDAC1 Q13547 4/20 0.41
HDAC6 Q9UBN7 4/20 0.41
HTR7 P34969 1/20 0.41
HSD11B1 P28845 1/20 0.39
POLB P06746 1/20 0.39
HTR1A P08908 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578893 0.82 HDAC1 (0.46) SMN1; SMN2HDAC1HDAC6HSD11B1POLB
SCHEMBL5578491 0.78 GLRA3 (0.41) SMN1; SMN2LMNAHTTALDH1A1HDAC1
SCHEMBL5578503 0.77 HDAC1 (0.50) HDAC1HDAC6POLBTSHRNPSR1
SCHEMBL5578589 0.75 HDAC1 (0.46) HDAC1HDAC6POLBTSHR
SCHEMBL5578454 0.73 HDAC1 (0.44) ALDH1A1HDAC1HDAC6POLBTSHR
SCHEMBL5578487 0.71 GRIN2B (0.60) LMNAALDH1A1HDAC1HDAC6USP2
SCHEMBL13824610 0.65 CYP2D6 (0.45) SMN1; SMN2ALDH1A1HDAC1HDAC6USP2
SCHEMBL17969882 0.65 HTR6 (0.46) LMNAOXTRHDAC1HDAC6TSHR
SCHEMBL5578474 0.65 SMN1; SMN2 (0.51) SMN1; SMN2LMNAHTTALDH1A1HSD11B1
SCHEMBL5251544 0.64 LMNA (0.78) SMN1; SMN2LMNAHTTHSD11B1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US claimed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO claimed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL SMN1; SMN2 236/4885LMNA 471/4885HTT 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.